Skip to content

PTSD: all studies

Page 109 of 211: studies 1,081 to 1,090 of 2,101, newest first. Back to the PTSD overview

Research

Psilocybin induces sex- and context-specific recruitment of the stress axis

Current Biology December 9, 2025 Sarah G. Cook, Stephanie J. Lee, Emma Ference et al. 3 citations

Following decades of prohibition, psychedelic drugs have reemerged as promising therapeutics for stress-related conditions, including depression and post-traumatic stress disorder. Still, their impact on stress-related brain regions and the hypothalamic-pituitary-adrenal (HPA) axis remains unclear. This work explores the acute effects of psilocybin on the primary regulators of the HPA axis:...

Cannabidiol Reduces D1 and D2 Medium Spiny Neuron Excitability in the Nucleus Accumbens Core.

bioRxiv : the preprint server for biology December 5, 2025 Zev E Jarrett, Brad A Grueter preprint

Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid constituent of the cannabis plant that shows promise for the treatment of a variety of neuropsychiatric disorders such as anxiety disorders, post-traumatic stress disorder, and substance use disorders. The nucleus accumbens (NAc) is a key brain region in the etiologies of these disorders and is actively modulated by CBD. Prior research...

Ibogaine’s potential role in supporting reward system recovery across diagnostic boundaries

Frontiers in Pharmacology December 4, 2025 Maya Nicolas

This article proposes that ibogaine’s induction of GDNF, modulation of glutamate and dopamine signaling, and reopening of plasticity represent a unified mechanism capable of restoring reward system fidelity across disorders. This includes addiction, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and eating disorders, amongst others. These conditions are labelled as...

Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges

Advanced Neurology December 4, 2025 Taslim Uddin, Sharmin Akter, Kaustabh Ghosh

Psychedelics are gaining recognition for their effectiveness as modulators of neuroplasticity in the treatment of a range of neuropsychiatric disorders. Psilocybin, lysergic acid diethylamide, N,N-dimethyltryptamine, and ketamine are substances that mainly affect the serotonergic and glutamatergic systems. They induce rapid synaptogenesis, dendritic remodeling, and changes in functional...

Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights

ACS Chemical Neuroscience December 2, 2025 Nina Kastner, Núria Nadal‐gratacós, Selina Hemmer et al.

3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD), resulting in breakthrough status. However, concerns regarding MDMA's abuse potential and cytotoxicity have sparked interest in developing safer analogues with similar therapeutic benefits. This study investigated the pharmacological properties of...

DOI: 10.1021/acschemneuro.5c00782 (opens in new tab) MDMA Norepinephrine transporter Monoamine neurotransmitter Dopamine transporter +8

Personalizing ketamine therapy: Real-world predictors of response to IV ketamine and intranasal esketamine in treatment-resistant depression.

Psychiatry Research December 1, 2025 Ahmed Z Elmaadawi, Imane Naha, Shruti Prabhudesai et al. 2 citations

Treatment-resistant depression (TRD) poses significant clinical challenges, often necessitating alternative treatments such as intravenous (IV) ketamine or intranasal esketamine. This study compared the effectiveness of these modalities and examined predictors of treatment response, including comorbidity profile, prior antidepressant failures, age, and gender. A retrospective chart review was...

MINDFULNESS IN MODERN COGNITIVE- BEHAVIORAL PSYCHOTHERAPY

Kyiv journal of modern psychology and psychotherapy November 30, 2025 Denys Starkov

The relevance of the research topic. The article is devoted to an overview of mindfulness technology and its application in psychological practice and cognitive- behavioral therapy. The essence of mindfulness practice is described and a historical sketch of its emergence and development is made. Research methodology. Theoretical models of mindfulness are considered, including the decentering...

A meta-analytic analysis of the acute effects of MDMA on empathy and emotion recognition in humans

Scientific Reports November 29, 2025 Leehe Peled-Avron, Jacob S. Aday, Madeline M. Pantoni et al. 1 citation

3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative known as an "entactogen," influencing emotional and social processing. Phase III clinical trials of MDMA-assisted psychotherapy for post-traumatic stress disorder have reported promising results, and MDMA-assisted therapy is currently under regulatory review. However, the precise mechanisms underlying positive treatment...

Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study

Scientific Reports November 27, 2025 Guy Simon, Nir Tadmor, Michael Skragge et al. 6 citations

This mixed-methods study examines how participant-identified childhood or youth trauma resurfaces during psychedelic states and how such episodes relate to post-experience trajectories. Including events participants identified as traumatic during psychedelic experiences, and subsequent psychological outcomes, both positive and negative. While psychedelics can facilitate emotional processing of...

DOI: 10.1038/s41598-025-26198-4 (opens in new tab) Full text (opens in new tab) Confusion Thematic analysis Perception Emotional distress +9

MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial

Journal of Psychiatric Research November 27, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Joanna Róg et al. 3 citations

BACKGROUND: Major depressive disorder (MDD) is a leading cause of global disability, and current treatments often fail to provide sustained effectiveness. MDMA-assisted therapy (MDMA-AT) is a promising treatment for MDD. However, the long-term effects are not known. OBJECTIVES: To examine the long-term effects of MDMA-AT for MDD. METHODS: Twelve participants with MDD and an ongoing moderate to...

DOI: 10.1016/j.jpsychires.2025.11.030 (opens in new tab) Major depressive disorder Depression economics Proof of concept Depressive symptoms +4